大名城(600094.SH):控股股東質押展期1.16億股
格隆匯4月15日丨大名城(600094.SH)公佈,公司於2020年4月15日收到公司控股股東名城企業管理集團有限公司(“名城企業集團”)的通知,獲悉其質押給申萬宏源證券有限公司的股票辦理了股票質押式回購交易延期購回,質押展期1.16億股,佔其所持股份比例49.24%,佔公司總股本比例4.69%。
名城企業管理集團有限公司為公司控股股東,持有公司A股股份2.36億股,佔公司總股本的9.52%。此次股份質押後,名城企業管理集團有限公司累計質押股份1.16億股,佔其所持公司股份總數的49.24%,佔控股股東及其一致行動人所持有的公司股份的13.96%,佔公司總股本的4.69%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.